Patents by Inventor Dana Kennedy

Dana Kennedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20240076402
    Abstract: Methods for using anti-LIV1 antibodies, including drug conjugated anti-LIV1 antibodies, to inhibit proliferation of a LIV-1-expressing cell, as well as for the treatment of one or more diseases or disorders associated with LIV-1-expressing cells (e.g., a LIV-1-associated breast cancer), are provided.
    Type: Application
    Filed: March 7, 2023
    Publication date: March 7, 2024
    Inventors: Dana KENNEDY, Ana KOSTIC, Elizabeth CORWIN, Jonathan DRACHMAN, Peter HAUGHNEY, Baiteng ZHAO, Phillip GARFIN, Maria Corinna PALANCA-WESSELS, Oyewale O. ABIDOYE
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 11559558
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: January 24, 2023
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20220288152
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 15, 2022
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 11369658
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 28, 2022
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20210315962
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: June 25, 2021
    Publication date: October 14, 2021
    Applicant: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Combination of CD33 antibody drug conjugates with chemotherapeutic agents
    Patent number: 11110179
    Abstract: This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 7, 2021
    Assignee: Seagen Inc.
    Inventors: Dana Kennedy, Eric Feldman
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 11077164
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: August 3, 2021
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20210138020
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 13, 2021
    Applicant: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 10940178
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: March 9, 2021
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 10912813
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 9, 2021
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20200306336
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20200283540
    Abstract: Methods for using anti-LIV1 antibodies, including dmg conjugated anti-LIV1 antibodies, to inhibit proliferation of a LIV-1-expressing cell, as well as for the treatment of one or more diseases or disorders associated with LIV-1-expressing cells (e.g., a LIV-1-associated breast cancer), are provided.
    Type: Application
    Filed: November 30, 2018
    Publication date: September 10, 2020
    Inventors: Dana KENNEDY, Ana KOSTIC, Elizabeth CORWIN, Jonathan DRACHMAN, Peter HAUGHNEY, Baiteng ZHAO, Phillip GARFIN, Corinna PALANCA-WESSELS, Oyewale O. ABIDOYE
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 10722549
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: July 28, 2020
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20200030405
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 30, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 10478469
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A? is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 19, 2019
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20190224268
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A? is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Eric SIEVERS, Dana Kennedy
  • COMBINATION OF CD33 ANTIBODY DRUG CONJUGATES WITH CHEMOTHERAPEUTIC AGENTS
    Publication number: 20190134215
    Abstract: This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 9, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Dana Kennedy, Eric Feldman
  • COMBINATIONS OF CD33 ANTIBODY DRUG CONJUGATES WITH HYPOMETHYLATING AGENTS
    Publication number: 20190117787
    Abstract: This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with hypomethylating agents.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 25, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Dana Kennedy, Megan O'Meara, Eric J. Feldman
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20180369317
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: September 11, 2018
    Publication date: December 27, 2018
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
    Patent number: 10098963
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: October 16, 2018
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy